Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
ChemoCentryx Inc. (NASDAQ: CCXI) shares declined 3.35 percent to close at $6.05 a share Monday. The stock traded between $5.90 and $6.34 on volume of 594,140 shares traded. Analysts at Goldman Sachs have recently initiated coverage on the company with a "neutral" rating and a price target of $7.00. Shares of ChemoCentryx have fallen approximately 450.0 percent in the past year.
Find out more about ChemoCentryx including full access to the free equity report at:
Corcept Therapeutics Inc. (NASDAQ: CORT) shares declined 13.07 percent to close at $3.26 a share Monday. The stock traded between $3.15 and $3.52 on volume of 1.15 million shares traded. Analysts at Stifel have recently downgraded the company’s rating to "hold" from "buy'. Shares of Corcept Therapeutics have gained approximately 65.0 percent in the past year.
Find out more about Corcept Therapeutics including full access to the free equity report at:
Select Medical Holdings Corp. (NYSE: SEM) shares gained 5.02 percent to close at $11.09 a share Monday. The stock traded between $10.86 and $11.13 on volume of 1.97 million shares traded. Analysts at Susquehanna have recently upgraded the company’s rating to "positive" from "neutral". Shares of Select Medical Holdings have gained approximately 15.0 percent in the past year.
Find out more about Select Medical Holdings including full access to the free equity report at:
Ventas, Inc. (NYSE: VTR) shares declined 1.32 percent to close at $59.90 a share Monday. The stock traded between $59.37 and $61.10 on volume of 2.82 million shares traded. Analysts at RBC Capital Markets have recently upgraded the company’s rating to "top pick" from "outperform". Shares of Ventas have gained approximately 90.0 percent in the past year.
Find out more about Ventas including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...